Stockscreener 앱 받기
164.42
2.46%
-4.15
Biogen Inc 주식(BIIB)의 최신 뉴스
The Truth About Biogen Inc: Is Wall Street’s New Alzheimer’s Obsession Worth Your Money? - AD HOC NEWS
Strong Cash Yield: Is Biogen Stock A Buy? - Trefis
Biogen Inc.: Can an Aging Neurology Giant Reinvent Itself Around Alzheimer’s? - AD HOC NEWS
Biogen (BIIB) Valuation Check As High Dose Spinraza Wins Key European Approval - simplywall.st
June 2027 Options Now Available For Biogen (BIIB) - Nasdaq
Biogen Inc. (NASDAQ:BIIB) Short Interest Update - MarketBeat
Nordea Investment Management AB Has $18.20 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Wednesday when compared to competitors - MSN
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Genentech, NoNO, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell - Barchart.com
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma (NASDAQ:BIIB) - Seeking Alpha
Europe clears Biogen’s high-dose Spinraza regimen - The Pharma Letter
Biogen Inc.: Can a Neuroscience Pioneer Still Out-Innovate the Biotech Pack? - AD HOC NEWS
Biogen (NASDAQ:BIIB) Shares Down 5.9%Time to Sell? - MarketBeat
Biogen falls after flagging $222 million charge to profit in Q4 - TradingView — Track All Markets
JPM26: With Leqembi Launched, Biogen Looks To Expand Alzheimer’s Presence - BioSpace
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com Australia
What to Expect From Biogen's Next Quarterly Earnings Report - Barchart.com
Biogen Sees $1.26 Per Share Impact From IPR&D, Milestone Expenses In Q4 - Nasdaq
Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly By Investing.com - Investing.com South Africa
Biogen sees Q4 IPR&D impacts on EPS by ~$1.26/share - MSN
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways - GlobeNewswire Inc.
Biogen Expects Q4 Expense of $222 Million - marketscreener.com
Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB) - The Globe and Mail
Biogen (BIIB) Anticipates Significant Q4 2025 Financial Impact f - GuruFocus
BiogenCharge to impact Q4 net income by $1.26 per shareSEC filing - marketscreener.com
Biogen’s Q4 preliminary EPS comes in below consensus By Investing.com - Investing.com Canada
Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com
The Bull Case For Biogen (BIIB) Could Change Following EU Approval Of High‑Dose Spinraza Regimen - simplywall.st
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Is There Still Value In Biogen (BIIB) After The Recent Share Price Recovery - Yahoo Finance
Biogen stock outlook remains positive as RBC reiterates Outperform rating By Investing.com - Investing.com UK
Biogen on the hunt for acquisition after $1B in cuts, 15% workforce reduction - The Business Journals
GRIMES & Co WEALTH MANAGEMENT LLC Sells 5,727 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy - Nasdaq
Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference - Yahoo Finance
United States Biosimilars and Biologics Market to hit US$ 532.13 - openPR.com
Biogen (BIIB) Gains European Approval for High Dose SPINRAZA Reg - GuruFocus
Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial - TipRanks
Biogen says co received European Commission approval for high dose regimen of Spinraza - marketscreener.com
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy - Biogen
Higher-dose spinal muscular atrophy treatment approved for patients in EU - Stock Titan
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs - Reuters
Biogen Inc. (BIIB) Stock Analysis: Navigating a 1.82% Potential Upside Amid Strategic Developments - DirectorsTalk Interviews
Spinal Muscular Atrophy Market Set for Rapid Growth, Demand, - openPR.com
Biogen (BIIB) Advances with Zorevunersen Development Program - GuruFocus
Trial of new Dravet syndrome drug moves faster, with key results in 2027 - Stock Titan
Cerity Partners LLC Increases Position in Biogen Inc. $BIIB - MarketBeat
3 Reasons to Sell BIIB and 1 Stock to Buy Instead - Finviz
Here's What Analysts Think About Biogen Inc. (BIIB) - Finviz
Here’s What Analysts Think About Biogen Inc. (BIIB) - Insider Monkey
EBIT per share of Biogen Inc. – DUS:IDP - TradingView — Track All Markets
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail - MSN
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy - TipRanks
Bernstein Adjusts Price Target on Biogen to $197 From $157, Maintains Market Perform Rating - marketscreener.com
Biogen’s Alzheimer’s Treatment Gains Crucial Momentum in Chinese Market - AD HOC NEWS
Assessing Biogen (BIIB) Valuation After China Accepts Subcutaneous LEQEMBI Application - simplywall.st
Responsive Playbooks and the BIIB Inflection - Stock Traders Daily
How Biogen Inc. stock performs in high volatility marketsJobs Report & Weekly Watchlist of Top Performers - ulpravda.ru
Will Biogen Inc. stock continue dividend increasesJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
How Biogen Inc. stock compares to growth peersEarnings Growth Summary & Verified Entry Point Detection - ulpravda.ru
Guidance Update: Will Biogen Inc. stock split again soonJuly 2025 EndofMonth & Fast Momentum Stock Entry Tips - ulpravda.ru
What catalysts could drive Biogen Inc. stock higherJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - ulpravda.ru
Truist Securities Raises Price Target for Biogen (BIIB) Amid Hol - GuruFocus
Goldman Sachs Adjusts Price Target on Biogen to $225 From $197, Maintains Buy Rating - marketscreener.com
RBC Raises Price Target on Biogen to $220 From $210, Keeps Outperform Rating - marketscreener.com
Biogen Inc. (NASDAQ:BIIB) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Mizuho raises Biogen stock price target to $207 on improved 2026 catalyst outlook - Investing.com Canada
1.85%
3.01%
자본화:
|
볼륨(24시간):